Related Experiment Video
Updated: Jul 19, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Yes, we have the power to end TB!
Nibedita Rath1, Chaitali Nikam2, Stephanie Seidel3
1Union Lung Health, South East Asia Region, New Delhi, India; Open Source Pharma Foundation, National Institute of Advanced Studies, Faculty Block, Indian Institute of Science Campus, Bangalore, 560012, India.
Ending tuberculosis (TB) requires sustained efforts and new technologies. Collaborative, cross-sectoral action is crucial to overcome research and development challenges and ensure equitable access to TB services.
Area of Science:
- Public Health
- Infectious Disease Research
- Global Health Initiatives
Background:
- Tuberculosis (TB) eradication efforts face challenges due to uneven progress and persistent issues.
- The End TB Strategy emphasizes developing new technologies by 2025 to accelerate TB incidence reduction.
Purpose of the Study:
- To address persistent challenges and disparities in TB research, development, and service delivery.
- To foster a cross-sectoral approach for equitable distribution of medical and programmatic innovations.
- To reaffirm the commitment to ending TB globally through collaborative action.
Main Methods:
- A Round Table discussion was convened on World TB Day 2023, involving SEAR Union, TB Alliance, NIAS, and OSPF.
- The discussion focused on the theme: "YES, WE HAVE THE POWER TO END TB!"
- Key areas for collaborative effort were identified, including R&D, access to services, prevention, surveillance, and stigma reduction.
Main Results:
- The discussion highlighted the possibility of achieving the goal to end TB.
- Commitment was made to collaborative efforts focusing on patient-centered approaches.
- Advocacy for strengthened TB service access, control, prevention, surveillance, and R&D investment was declared.
Conclusions:
- Overcoming existing difficulties and discrepancies in TB research and development is a priority.
- Integrating patient voices and reducing stigma are essential components of the strategy.
- The Round Table serves as a framework to ensure the achievability of ending TB.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

